Pfizer Biosimilars Sales Hit $1.5bn In 2020 As US Revenues Double
Three Oncology Launches Help Drive Growth In US
Pfizer’s US biosimilars sales approached $1bn last year, following a number of launches and continued uptake for key products, while revenues in international markets, especially Europe, also increased.
